ClinicalTrials.gg
RecruitingNCT06161025Updated Oct 26, 2026

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Phase 2/3 interventional study of R-DXd and Paclitaxel in Solid Cancer, sponsored by Daiichi Sankyo. Recruiting at 167 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Daiichi Sankyo · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.
Updated Oct 26, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
860
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Ovarian Neoplasms by Daiichi Sankyo — 5 open to participants now, 6 under way, 3 of them phase 3. Ovarian Neoplasms · Daiichi Sankyo.

Started
2024
with 2 others
Phase 2/3
Only one
of the 12
Registered
7th of 12
by date

Among the 12 studies in Ovarian Neoplasms by Daiichi Sankyo, this one is one of 3 that started in 2024, is the only one in phase 2/3, and was the 7th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 12 studies in Ovarian Neoplasms by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ovarian Neoplasms by Daiichi Sankyo, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Read the detailed description

This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator's choice of chemotherapy and further evaluate efficacy.

03

Conditions studied

  • Solid Cancer

Keywords

  • Primary pertioneal cancer
  • Ovarian cancer
  • Fallopian tube cancer
  • Raludotatug Deruxtecan (R-DXd)
  • Cadherin 6 (CDH6)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign and date the form prior to the start of any study-specific qualification procedures.
  • Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
  • Participants with or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer.
  • For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to , and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen.
  • For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy:

    • +/-adjuvant considered 1 .
    • Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors) will be considered part of the preceding line of therapy.
    • Therapy changed due to toxicity in the absence of progression will be considered part of the same line.
    • Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance.
    • At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study.
  • Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between >90 and ≤180 days after the date of the last dose of platinum If a subject had 2 or 4 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.
  • If mirvetuximab soravtansine (MIRV) is locally available: Has had prior treatment with MIRV for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally.
  • Has at least 1 evaluated by computed tomography or magnetic resonance imaging according to version 1.1 (RECIST v1.1) per investigator assessment.
  • performance status of 0 or 1.
  • Has adequate organ and bone marrow function as assessed by local laboratory (within 14 days before start of study drug administration).
  • Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions.
  • For Phase 3 (Part B) only: Subjects must be eligible for one of the treatments included in the investigator's choice of chemotherapy arm.

Exclusion criteria

Exclusion Criteria

  • Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline OVC. (Note for Phase 3 [Part B]: seromucinous, low-grade serous carcinoma or ovarian sarcoma, carcinosarcoma and undifferentiated carcinoma are excluded.)
  • Inadequate before Cycle 1 Day 1, defined as follows:

    • Major surgery \<28 days
    • Radiation therapy \<28 days (if palliative stereotactic radiation therapy without abdominal radiation, ≤14 days)
    • Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) \<28 days or 5 half-lives, whichever is shorter, before starting study drug
    • Chloroquine/hydroxychloroquine \<14 days
    • Exposure to another drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures
  • Clinically active , spinal cord compression, or , defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion A minimum of 2 weeks must have elapsed between the end of radiotherapy and randomization and there should be no evidence of progression or need for steroid treatment or anticonvulsants for at least 2 weeks prior to randomization. Note: If there is a history or suspicion of central nervous system. Note: If there is a history or suspicion of central nervous system , a CT scan of the head or MRI of the brain must be performed at baseline.
  • Any of the following within the past 6 months prior to randomization: cerebrovascular accident, , or other arterial thromboembolic event.
  • Uncontrolled or significant cardiovascular disease, including the following:

    • corrected with Fridericia's formula interval >470 ms.
    • Diagnosed or suspected long QT syndrome.
    • History of ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
    • The participant has bradycardia of less than 50 bpm, unless the subject has a pacemaker.
    • History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
    • Myocardial infarction within 6 months prior to screening.
    • Uncontrolled angina pectoris within 6 months prior to screening.
    • Class 3 or 4 congestive heart failure.
    • \<50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan.
    • Coronary/peripheral artery bypass graft within 6 months prior to screening
    • Uncontrolled hypertension (HgCTCAE Grade ≥3 hypertension as per version 5.0).
    • Complete left or right bundle branch block.
  • Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe (COPD), restrictive lung disease, pleural effusion, etc) and any , connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy.
  • Chronic steroid treatment (>10 mg/day), with the exception of the following:

    • Inhaled steroids for asthma or COPD
    • Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension
    • Topical steroids for mild skin conditions
    • Low-dose supplemental corticosteroids for adrenocortical insufficiency
    • Premedication for treatment groups and/or premedication in case of any
    • Intra-articular steroid injections
  • History of other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer).
  • Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade ≤1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade >2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following:

    • Chemotherapy-induced neuropathy
    • Fatigue
    • Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency
    • Skin pigmentation (vitiligo)
  • For Phase 2 (Part A): Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan). For Phase 3 (Part B): Prior exposure to other CDH6-targeted agents or an antibody-drug conjugate containing a topoisomerase I inhibitor.
  • History of hypersensitivity to any in the R-DXd or any known to treatment with, including hypersensitivity to, the study drug(s).
  • Has an active or uncontrolled (HIV) infection.
  • Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
  • Has an active or uncontrolled virus (HBV) or virus (HCV) infection. Hepatitis B and Hepatitis C Screening tests are required.

Subjects are eligible if:

  1. Hepatitis B virus surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization.
  2. History of hepatitis C infection: eligible if the HCV viral load is below the level of detection in the absence of antiviral therapy during the previous 4 weeks.
  3. Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of /ALT \<3 × , which are not attributable to HCV infection.

    • Female who is pregnant or breastfeeding or intends to become pregnant during the study.
    • Psychological, social, familial, or geographical factors that would prevent regular follow-up.
    • Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
    • Has a history of receiving (messenger RNA [mRNA] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
    • For Phase 3 (Part B) only: Has clinical symptoms or radiographic evidence of intestinal obstruction.
    • For Phase 3 (Part B) only: Has ascites or pleural effusions that require repeated drainage (less than 4 weeks between drainages).
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
860 participants (estimated)

Study arms

  • Experimental
    Part A: R-DXd 4.8mg/kg Q3W

    Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).

    Drug: R-DXd

  • Experimental
    Part A: R-DXd 5.6 mg/kg Q3W

    Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).

    Drug: R-DXd

  • Experimental
    Part A: R-DXd 6.4 mg/kg Q3W

    Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).

    Drug: R-DXd

  • Experimental
    Part B: R-DXd RP3D Q3W

    Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).

    Drug: R-DXd

  • Active comparator
    Part B: Investigator's Choice

    Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), or topotecan.

    Drug: Paclitaxel · Drug: Topotecan · Drug: PLD

Interventions

  • DrugR-DXd

    R-DXd will be administered as an intravenously (IV) infusion

    Also known as: DS-6000a

  • Paclitaxel will be administered as an IV infusion

  • Topotecan will be administered as an IV infusion

  • DrugPLD

    PLD will be administered as an IV infusion

    Also known as: Pegylated Liposomal Doxorubicin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)

    The ORR was defined as the percentage of participants with confirmed Complete Response (CR) or Partial Response (PR), by BICR assessment based on RECIST version 1.1.

    Time frame: From date of randomization to data cut off, up to 18 months

  2. Progression-free Survival (PFS) Based on BICR Assessment (Part B)

    PFS is defined as the time from the date of randomization to the date of disease progression, defined as the first documented radiological progression or death due to any cause, whichever comes first.

    Time frame: From date of randomization to data cut off, up to 26 months

Secondary outcomes

  1. Objective Response Rate (ORR) Based on Investigator Assessment

    The ORR was defined as the percentage of participants who achieved Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), by Investigator assessment based on RECIST version 1.1.

    Time frame: From date of randomization to data cut off, up to 30 months

  2. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: From date of randomization to data cut off, up to 40 months

  3. Duration of Response (DOR)

    DoR is defined as the time from the date of the first documentation of objective tumor response (CR or PR) that is subsequently confirmed to the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: From date of randomization to data cut off, up to 40 months

  4. Progression-free Survival (PFS) Based on BICR and Investigator Assessment

    PFS is defined as the time from the date of randomization to the date of disease progression, defined as the first documented radiological progression or death due to any cause.

    Time frame: From date of randomization to data cut off, up to 30 months

  5. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants who achieved a confirmed CR, PR, or stable disease maintained for ≥12 weeks, as assessed by BICR and investigator based on RECIST version 1.1

    Time frame: From date of randomization to data cut off, up to 40 months

  6. Time to Next Treatment (TTNT)

    TTNT is defined as the time from randomization to the start date of the next line of therapy

    Time frame: From date of randomization to data cut off, up to 40 months

  7. Progression-free Survival 2 (PFS2) Based on Investigator Assessment

    PFS2 is defined as the time from randomization to the first documented objective disease progression on next line therapy or death due to any cause, whichever comes first.

    Time frame: From date of randomization to data cut off, up to 40 months

  8. Percentage of Participants With Cancer Antigen 125 (CA-125) Response Rate

    CA-125 response rate is defined as the percentage of participants with a reduction of 50% in CA-125 levels when compared to levels from a pretreatment sample, as assessed by blood sample based on Gynecological Cancer InterGroup criteria

    Time frame: From baseline to data cut off, up to 40 months

  9. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    TEAEs are defined as those AEs with a start or worsening date during the on-treatment period (from the first dose date to 40 days after the last dose date of study treatment).

    Time frame: From first dose to data cut off, up to 40 months

  10. Pharmacokinetic (PK) Analysis: Maximum Plasma Drug Concentration (Cmax) of R-DXd

    Time frame: From first dose to data cut off, up to 40 months

  11. Pharmacokinetic (PK) Analysis: Time to Reach Maximum Plasma Drug Concentration (Tmax) of R-DXP

    Time frame: From first dose to data cut off, up to 40 months

  12. Pharmacokinetic (PK) Analysis: Area Under the Concentration-Time Curve (AUC) of R-DXd

    Time frame: From first dose to data cut off, up to 40 months

  13. Percentage of Participants With Treatment Emergent Antidrug Antibody (ADA)

    Time frame: From baseline to data cut off, up to 40 months

  14. Pharmacokinetic (PK) Analysis: Terminal Half-Life (t1/2) of R-DXd

    Time frame: From first dose to data cut off, up to 40 months

  15. Change from Baseline in Abdominal/gastrointestinal (GI) Symptoms (Part B)

    Change from baseline in abdominal and gastrointestinal symptoms as measured by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) OV28 abdominal/GI subscale

    Time frame: From baseline to Week 12 and up to data cut off, up to 40 months

  16. Change from Baseline in Fatigue/Pain Symptoms (Part B)

    Change from baseline as measured by the EORTC QLQ C30 Fatigue/Pain subscale score

    Time frame: From baseline to data cut off, up to 40 months

  17. Time to Deterioration in Fatigue/Pain Symptoms (Part B)

    Time to deterioration in pain from baseline as measured by the EORTC QLQ C30 Fatigue/Pain subscale score

    Time frame: From baseline to data cut off, up to 40 months

  18. Time to Deterioration in GI Symptoms (Part B)

    Time to deterioration in pain from baseline as measured by the EORTC QLQ OV28 abdominal/GI subscale total score

    Time frame: From baseline to data cut off, up to 40 months

  19. Time to Deterioration in Disease Impacts (Part B)

    Time to deterioration in selected subscales of EORTC QLQ C30; physical functioning, global health status, overall quality of life.

    Time frame: From baseline to data cut off, up to 40 months

  20. Change from Baseline in Disease Impacts (Part B)

    Change from Baseline in selected subscales of EORTC QLQ C30; physical functioning, global health status, overall quality of life.

    Time frame: From baseline to data cut off, up to 40 months

  21. Cadherin-6 (CDH6) protein expression in tumor tissue as determined by immunochemistry assay and correlation with ORR, DoR, PFS and OS

    CDH6 protein expression in tumor tissue as determined by immunohistochemistry.

    Time frame: From baseline to data cut off, up to 40 months

07

Study locations

29 of 167 sites recruiting
  • Alaska Women's Cancer Care
    Anchorage, Alaska 99508, United States
    Recruiting
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center at Lennar
    Coral Gables, Florida 33146, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Florida Cancer Specialists
    Lake Mary, Florida 32746, United States
    Recruiting
  • Sylvester Cancer Center
    Miami, Florida 33136, United States
    Recruiting
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
    Recruiting
  • Sylvester Comprehensive Cancer Center at Plantation
    Plantation, Florida 33324, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Community MD Anderson Cancer Center- East
    Indianapolis, Indiana 46219, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Community MD Anderson Cancer Center- South
    Indianapolis, Indiana 46227, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Community Health Network - MD Anderson
    Indianapolis, Indiana 46250, United States
    Recruiting
  • St. Vincent Gynecologic Oncology
    Indianapolis, Indiana 46260, United States
    Recruiting
  • St. Elizabeth Medical Center
    Edgewood, Kentucky 41017, United States
    Recruiting
  • Baystate Medical Center
    Springfield, Massachusetts 01199-1001, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine Obstetrics and Gynecology
    St Louis, Missouri 63110, United States
    Recruiting
  • Valley Health System
    Paramus, New Jersey 07652, United States
    Recruiting
  • Holy Name
    Teaneck, New Jersey 07666, United States
    Recruiting
  • NHPP Imbert
    Bay Shore, New York 11706, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwell Health, LLC PRIME
    Lake Success, New York 11042, United States
    Recruiting
  • Perlmutter Cancer Center at NYU Langone Hospital- Long Island
    Mineola, New York 11501, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
  • NHPP LHH
    New York, New York 10065, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novant Health Presbyterian Medical Center
    Charlotte, North Carolina 28204, United States
    Recruiting
  • Duke Women's Cancer Care- Raleigh
    Durham, North Carolina 27607, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Duke Cancer Center
    Durham, North Carolina 27710, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Ohio State University Wexner Medical Center
    Hilliard, Ohio 43026, United States
    Recruiting
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • Oklahoma Cancer Specialists and Research Institute
    Tulsa, Oklahoma 12967, United States
    Recruiting
  • Oncology Associates of Oregon, P.C.
    Eugene, Oregon 97401, United States
    Recruiting
  • Perelman School of Medicine at the University of Pennsylvania
    Philadelphia, Pennsylvania 19104-4238, United States
    Recruiting
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
    Recruiting
  • Sanford Cancer Center Gynecologic Oncology
    Sioux Falls, South Dakota 57104, United States
    Recruiting
  • Texas Oncology-Bedford
    Bedford, Texas 76022, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Houston Area Locations- Woodlands
    Conroe, Texas 77384, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Texas Oncology-Presbyterian Cancer Center Dallas
    Dallas, Texas 75231, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Texas Oncology Paris
    Fort Worth, Texas 76104, United States
    Recruiting
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
    Recruiting
  • University of Texas - MD Anderson
    Houston, Texas 77030, United States
    Recruiting
  • Houston Area Locations- Sugar Land
    Houston, Texas 77079, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Houston Area Locations- West Houston
    Houston, Texas 77079, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Houston Area Locations- League City
    League City, Texas 77573, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Virginia Comprehensive Cancer Center
    Charlottesville, Virginia 22903, United States
    Recruiting
  • University of Washington - Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
    Recruiting
  • Froedtert and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • GenesisCare St Andrews Hospital
    Adelaide, 5000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Peter MacCallum Cancer Center
    Melbourne, 3000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Gold Coast University Hospital
    Southport, 4215, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • GenesisCare North Shore (Oncology)
    St Leonards, 2065, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Oncocentro - Belo Horizonte
    Belo Horizonte, 30360680, Brazil
    Recruiting
  • Hospital Ernesto Dornelles
    Porto Alegre, 90.160-093, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hospital Moinhos de Vento
    Porto Alegre, 90035-001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Instituto COI de Pesquisa
    Rio de Janeiro, 22775-001, Brazil
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Arthur J. E. Child Comp CC
    Calgary, Alberta T2N 5G2, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • London Health Sciences Centre (LHSC) - Victoria Hospital
    London, N6A5W9, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • McGill University Health Centre/Glen Site / Royal Victoria Hospital
    Montreal, H4A 3J1, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The Ottawa Hospital Cancer Centre
    Ottawa, K1H 8L6, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University Health Network - Princess Margaret Cancer Centre
    Toronto, M5G 2M9, Canada
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Xi'An Jiaotong University
    Xi’an, Shanxi 710061, China
    Recruiting
  • Beijing Cancer Hospital
    Beijing, 100142, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Chongqing Cancer Hospital
    Chongqing, 400030, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fujian Provincial Cancer Hospital
    Fuzhou, 350015, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Qilu Hospital of Shandong University
    Jinan, 250117, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Shandong Cancer Hospital
    Jinan, 250117, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Guangxi Medical University Cancer Hospital
    Nanning, 530021, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, 453000, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, 430022, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hubei Cancer Hospital
    Wuhan, 430079, China
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 50005, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Vseobecna fakultni nemocnice v Praze
    Prague, 128 08, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice v Motole
    Prague, 150 06, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Fakultni nemocnice Bulovka
    Prague, 180 81, Czechia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kuopio University Hospital
    Kuopio, 70210, Finland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Bergonié
    Bordeaux, 33076, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Francois Baclesse
    Caen, 14076, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Jean Perrin - CLCC
    Clermont-Ferrand, 63000, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Georges François Leclerc
    Dijon, 21079, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Centre Leon Berard
    Lyon, 69008, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Paoli Calmettes
    Marseille, 13273, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut du Cancer de Montpellier
    Montpellier, 34298, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hôpital Privé du Confluent
    Nantes, 44277, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Groupe Hospitalier Diaconesses - Hôpital De La Croix Saint Simon
    Paris, 75571, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    Plérin, 22190, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Institut Curie
    Saint-Cloud, 92210, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • ICL Alexis Vautrin
    Vandœuvre-lès-Nancy, 54500, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Carl Gustav Carus TU Dresden
    Dresden, 01307, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Kliniken Essen-Mitte
    Essen, 45136, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Hamburg-Eppendorf (Ph3)
    Hamburg, 20246, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Mannheim
    Mannheim, 68167, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Universitaetsklinikum Ulm
    Ulm, 89075, Germany
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Aretaieio Hospital
    Athens, 11528, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Diagnostic and Therapeutic Centre of Athens "Hygeia" S.A.
    Marousi, 15123, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IASO General Clinic
    Marousi, 15123, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St Luke's Hospital
    Thessaloniki, 55236, Greece
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • IRCCS Centro di Riferimento Oncologico
    Aviano, 33081, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
    Bologna, 40138, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

Showing the first 100 of 167 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 7, 2023
StartActual
Feb 27, 2024
Primary completionEst.
Feb 29, 2028
CompletionEst.
Apr 30, 2030
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (2 United States, 1 China)
  • St. Vincent Gynecologic Oncology · Indianapolis, United States
  • Novant Health Presbyterian Medical Center · Charlotte, United States
  • The First Affiliated Hospital of Xi'An Jiaotong University · Xi’an, China
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    3 sites added
    Show 3 added (2 United States, 1 China)
    • St. Vincent Gynecologic Oncology · Indianapolis, United States
    • Novant Health Presbyterian Medical Center · Charlotte, United States
    • The First Affiliated Hospital of Xi'An Jiaotong University · Xi’an, China

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06161025
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 7, 2023
Start date
Feb 27, 2024
Primary completion
Feb 29, 2028 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 26, 2026

Study contacts

Medical Director Contact for Clinical Trial Information
Contact
CTRinfo_us@daiichisankyo.com
908-992-6400
Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Raludotatug deruxtecan

Start the discussion